The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Advances in ovarian cancer therapy
Open accessAbstract
Epithelial ovarian cancer is typically diagnosed at an advanced stage. Current state-of-the-art surgery and chemotherapy result in the high incidence of complete remissions; however, the recurrence rate is also high. For most patients, the disease eventually becomes a continuum of symptom-free periods and recurrence episodes. Different targeted treatment approaches and biological drugs, currently under development, bring the promise of turning ovarian cancer into a manageable chronic disease. In this review, we discuss the current standard in the therapy for ovarian cancer, major recent studies on the new variants of conventional therapies, and new therapeutic approaches, recently approved and/or in clinical trials. The latter include anti-angiogenic therapies, polyADP-ribose polymerase (PARP) inhibitors, inhibitors of growth factor signaling, or folate receptor inhibitors, as well as several immunotherapeutic approaches. We also discuss cost-effectiveness of some novel therapies and the issue of better selection of patients for personalized treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
du Bois, A., Reuss, A., Pujade‐Lauraine, E., Harter, P., Ray‐Coquard, I., & Pfisterer, J. (2009) · Cancer · doi:10.1002/cncr.24149 · Cited by 1,638
Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,622
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384
Staging classification for cancer of the ovary, fallopian tube, and peritoneum
Prat, J. (2014) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2013.10.001 · Cited by 1,364
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196 · cited 2×
“, according to the appraisal by NICE, the ICER for olaparib maintenance in platinum-sensitive relapsed ovarian cancer versus routine surveillance is likely to be more than £92,000 per QALY gained [90].”
BackgroundMethodMolecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm
Kurman, R. J., & Shih, I.-M. (2011) · Human Pathology · doi:10.1016/j.humpath.2011.03.003 · Cited by 1,073
Oza, A. M., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00086-8 · Cited by 875
Katsumata, N., Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., Tsuda, H., Sugiyama, T., Kodama, S., Kimura, E., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61157-0 · Cited by 727
Cho, K. R., & Shih, I.-M. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092246 · Cited by 694
Cancer immunotherapies targeting the PD-1 signaling pathway
Iwai, Y., Hamanishi, J., Chamoto, K., & Honjo, T. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0329-9 · Cited by 635
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Rustin, G. J., van der Burg, M. E., Griffin, C. L., Guthrie, D., Lamont, A., Jayson, G. C., Kristensen, G., Mediola, C., Coens, C., Qian, W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61268-8 · Cited by 599
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00007-1 · Cited by 594
Liu, J. F., Barry, W. T., Birrer, M., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B., Buss, M. K., Nattam, S., Hurteau, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 585
Heiss, M. M., Murawa, P., Koralewski, P., Kutarska, E., Kolesnik, O. O., Ivanchenko, V. V., Dudnichenko, A. S., Aleknaviciene, B., Razbadauskas, A., Gore, M., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25423 · Cited by 549
Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71135-0 · Cited by 547
Katsumata, N., Yasuda, M., Isonishi, S., Takahashi, F., Michimae, H., Kimura, E., Aoki, D., Jobo, T., Kodama, S., Terauchi, F., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70363-2 · Cited by 480
Targeting folate receptor alpha for cancer treatment
Cheung, A., Bax, H. J., Josephs, D. H., Ilieva, K. M., Pellizzari, G., Opzoomer, J., Bloomfield, J., Fittall, M., Grigoriadis, A., Figini, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9651 · Cited by 430
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
Chan, J. K., Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., Walker, J. L., DiSilvestro, P. A., Rubin, S. C., Martin, L. P., Davidson, S. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505067 · Cited by 367
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
Jaaback, K., Johnson, N., & Lawrie, T. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005340.pub4 · Cited by 359
Ledermann, J. A., Canevari, S., & Thigpen, T. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv250 · Cited by 347
Tumor promoting role of anti-tumor macrophages in tumor microenvironment
Goswami, K. K., Ghosh, T., Ghosh, S., Sarkar, M., Bose, A., & Baral, R. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.04.005 · Cited by 329
Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
du Bois, A., Floquet, A., Kim, J.-W., Rau, J., del Campo, J. M., Friedlander, M., Pignata, S., Fujiwara, K., Vergote, I., Colombo, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7348 · Cited by 328
Aghajanian, C., Goff, B., Nycum, L. R., Wang, Y. V., Husain, A., & Blank, S. V. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.08.004 · Cited by 320
Monk, B. J., Poveda, A., Vergote, I., Raspagliesi, F., Fujiwara, K., Bae, D.-S., Oaknin, A., Ray-Coquard, I., Provencher, D. M., Karlan, B. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70244-x · Cited by 304
Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer
Harter, P., Sehouli, J., Reuß, A., Hasenburg, A., Scambia, G., Cibula, D., Mahner, S., Vergote, I. B., Reinthaller, A., Burges, A., et al. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31820aaafd · Cited by 297
Homologous recombination deficiency and ovarian cancer
Ledermann, J. A., Drew, Y., & Kristeleit, R. S. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.005 · Cited by 258
Burges, A., Wimberger, P., Kümper, C., Gorbounova, V., Sommer, H., Schmalfeldt, B., Pfisterer, J., Lichinitser, M., Makhson, A., Moiseyenko, V., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2769 · Cited by 257
Ledermann, J. A., Embleton, A. C., Raja, F., Perren, T. J., Jayson, G. C., Rustin, G. J. S., Kaye, S. B., Hirte, H., Eisenhauer, E., Vaughan, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01167-8 · Cited by 237
Karlan, B. Y., Oza, A. M., Richardson, G. E., Provencher, D. M., Hansen, V. L., Buck, M., Chambers, S. K., Ghatage, P., Pippitt, C. H., Brown, J. V., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3178 · Cited by 224
Clinical Trials in Recurrent Ovarian Cancer
Friedlander, M., Trimble, E., Tinker, A., Alberts, D., Avall-Lundqvist, E., Brady, M., Harter, P., Pignata, S., Pujade-Lauraine, E., Sehouli, J., et al. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31821bb8aa · Cited by 224
Konecny, G. E., & Kristeleit, R. S. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.311 · Cited by 216
du Bois, A., Kristensen, G., Ray-Coquard, I., Reuss, A., Pignata, S., Colombo, N., Denison, U., Vergote, I., del Campo, J. M., Ottevanger, P., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00366-6 · Cited by 211
Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
Yap, T. A., Sandhu, S. K., Carden, C. P., & de Bono, J. S. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20095 · Cited by 208
Niraparib: First Global Approval
Scott, L. J. (2017) · Drugs · doi:10.1007/s40265-017-0752-y · Cited by 177
Pignata, S., Lorusso, D., Scambia, G., Sambataro, D., Tamberi, S., Cinieri, S., Mosconi, A. M., Orditura, M., Brandes, A. A., Arcangeli, V., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70115-4 · Cited by 164
Matulonis, U. A., Penson, R. T., Domchek, S. M., Kaufman, B., Shapira-Frommer, R., Audeh, M. W., Kaye, S., Molife, L. R., Gelmon, K. A., Robertson, J. D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw133 · Cited by 160
Armstrong, D. K., White, A. J., Weil, S. C., Phillips, M. D., & Coleman, R. L. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.03.002 · Cited by 153
The role of immune checkpoint inhibition in the treatment of ovarian cancer
Gaillard, S. L., Secord, A. A., & Monk, B. J. (2016) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-016-0033-6 · Cited by 153
Gotlieb, W. H., Amant, F. C., Advani, S. H., Goswami, C., Hirte, H. W., Provencher, D. M., Somani, N., Yamada, S., Tamby, J., & Vergote, I. B. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70338-2 · Cited by 151
Vergote, I. B., Marth, C., & Coleman, R. L. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9539-8 · Cited by 148
PARP inhibitors in ovarian cancer: Current status and future promise
Liu, J. F., Konstantinopoulos, P. A., & Matulonis, U. A. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.039 · Cited by 147
Sabbatini, P. J., Harter, P., Scambia, G., Sehouli, J., Meier, W., Wimberger, P., Baumann, K., Kurzeder, C., Schmalfeldt, B., Cibula, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.4057 · Cited by 145
Tewari, K. S., Java, J., Eskander, R. N., Monk, B. J., & Burger, R. A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv500 · Cited by 140
Recurrent epithelial ovarian cancer: an update on treatment.
Foley, O., Rauh‐Hain, J. A., & Carmen, M. G. D. (2013) · PubMed · Cited by 135
Ovarian cancer – from biology to clinic
Kujawa, K. A., & Lisowska, K. M. (2015) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/17322693.1184451 · Cited by 116
Self-citationRucaparib: First Global Approval
Syed, Y. Y. (2017) · Drugs · doi:10.1007/s40265-017-0716-2 · Cited by 115
Bakrin, N., Cotte, E., Golfier, F., Gilly, F. N., Freyer, G., Helm, W., Gléhen, O., & Béréder, J.-M. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2510-4 · Cited by 113
Karbach, J., Neumann, A., Brand, K., Wahle, C., Siegel, E., Maeurer, M. J., Ritter, E., Tsuji, T., Gnjatic, S., Old, L. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1116 · Cited by 113
Bevacizumab in ovarian cancer: A critical review of phase III studies
Rossi, L., Verrico, M., Zaccarelli, E., Papa, A., Colonna, M., Strudel, M., Vici, P., Bianco, V., & Tomao, F. (2016) · Oncotarget · doi:10.18632/oncotarget.13310 · Cited by 112
Malignant ascites in ovarian cancer and the role of targeted therapeutics.
Smolle, E., Taucher, V., & Haybaeck, J. (2014) · PubMed · Cited by 109
Rouzier, R., Gouy, S., Selle, F., Lambaudie, É., Floquet, A., Fourchotte, V., Pomel, C., Colombo, P., Kalbacher, E., Martin-Françoise, S., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.09.036 · Cited by 108
Borlak, J. T., Länger, F. P., Spanel, R., Schöndorfer, G., & Dittrich, C. (2016) · Oncotarget · doi:10.18632/oncotarget.8574 · Cited by 98
Gene Expression Analysis in Ovarian Cancer – Faults and Hints from DNA Microarray Study
Lisowska, K. M., Olbryt, M., Dudaladava, V., Pamuła-Piłat, J., Kujawa, K., Grzybowska, E., Jarząb, M., Student, S., Rzepecka, I. K., Jarząb, B., et al. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00006 · Cited by 97
Self-citationBignotti, E., Tassi, R. A., Calza, S., Ravaggi, A., Bandiera, E., Rossi, E., Donzelli, C., Pasinetti, B., Pecorelli, S. L., & Santin, A. D. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.10.874 · Cited by 96
Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, É., Park, Y. C., Parekh, T. V., & Poveda, A. M. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.001 · Cited by 95
Colombo, N., Mangili, G., Mammoliti, S., Kalling, M., Tholander, B., Sternas, L. A., Buzenet, G., & Chamberlain, D. H. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.11.021 · Cited by 94
Novel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab®)
Seimetz, D. (2011) · Journal of Cancer · doi:10.7150/jca.2.309 · Cited by 90
Ruf, P., Kluge, M., Jäger, M., Burges, A., Volovat, C. D., Heiss, M. M., Hess, J., Wimberger, P., Brandt, B., & Lindhofer, H. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03635.x · Cited by 88
Almeida, M. I., da Silva, A. M., Vasconcelos, D. M., Almeida, C. R., Caires, H. R., Pinto, M. T., Călin, G. A., Santos, S. G., & Barbosa, M. A. (2015) · Oncotarget · doi:10.18632/oncotarget.6589 · Cited by 88
Immunotherapeutic approaches to ovarian cancer treatment
Chester, C., Dorigo, O., Berek, J. S., & Kohrt, H. E. K. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0051-7 · Cited by 84
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
Papa, A., Caruso, D., Strudel, M., Tomao, F., & Tomao, F. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1027-1 · Cited by 80
Sabbatini, P. J., Dupont, J., Aghajanian, C. A., Derosa, F., Poynor, E. A., Anderson, S., Hensley, M. L., Livingston, P., Iasonos, A. E., Spriggs, D. R., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2670 · Cited by 73
Profile of nintedanib in the treatment of solid tumors: the evidence to date
Awasthi, N., & Schwarz, R. E. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s78805 · Cited by 71
Cancer Vaccines in Ovarian Cancer: How Can We Improve?
Lluesma, S. M., Wolfer, A., Harari, A., & Kandalaft, L. E. (2016) · Biomedicines · doi:10.3390/biomedicines4020010 · Cited by 67
Lisowska, K. M., Olbryt, M., Student, S., Kujawa, K. A., Cortez, A. J., Simek, K., Dansonka‐Mieszkowska, A., Rzepecka, I. K., Tudrej, P., & Kupryjańczyk, J. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2147-y · Cited by 66
Self-citationFitzsimmons, D. F., Gilbert, J., Howse, F., Young, T., Arrarras, J.-I., Brédart, A., Hawker, S., George, S. L., Aapro, M., & Johnson, C. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.07.036 · Cited by 61
Immunotherapy for Ovarian Cancer
Drerup, J. M., Yang, L., Padron, A. S., Murthy, K., Hurez, V. J., Zhang, B., & Curiel, T. J. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0317-1 · Cited by 59
Immunotherapy in ovarian cancer
Mantia-Smaldone, G. M., Corr, B. R., & Chu, C. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.20738 · Cited by 57
Lorusso, D., Scambia, G., Pignata, S., Sorio, R., Amadio, G., Lepori, S., Mosconi, A. M., Pisano, C., Mangili, G., Maltese, G., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv608 · Cited by 55
Immunotherapy in ovarian cancer
Krishnan, V., Berek, J. S., & Dorigo, O. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.11.003 · Cited by 54
Berek, J. S., Edwards, R. P., Parker, L. P., DeMars, L. R., Herzog, T. J., Lentz, S. S., Morris, R. T., Akerley, W., Holloway, R. W., Method, M. W., et al. (2014) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000286 · Cited by 51
Murata, S., Zhang, C., Finch, N., Zhang, K., Campo, L., & Breuer, E.-K. Y. (2016) · BioMed Research International · doi:10.1155/2016/2346585 · Cited by 51
Intraperitoneal immunotherapy: historical perspectives and modern therapy
Morano, W. F., Aggarwal, A., Love, P. N., Richard, S. D., Esquivel, J., & Bowne, W. B. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.49 · Cited by 50
Pujade-Lauraine, É., Ledermann, J. A., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A. M., Pignata, S., Friedlander, M. L., & Colombo, N. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.03.505 · Cited by 50
Baumann, K., Pfisterer, J., Wimberger, P., Burchardi, N., Kurzeder, C., du Bois, A., Loibl, S., Sehouli, J., Huober, J., Schmalfeldt, B., et al. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.06.004 · Cited by 49
Gray, H. J., Benigno, B. B., Berek, J. S., Chang, J., Mason, J. R., Mileshkin, L., Mitchell, P. L. R., Moradi, M., Recio, F. O., Michener, C. M., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0137-x · Cited by 48
Walker, J. L., Brady, M. F., DiSilvestro, P., Fujiwara, K., Ds, A., Zheng, W., Tewari, K. S., Cohn, D. E., Powell, M. A., Le, L. V., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.04.535 · Cited by 43
Bevacizumab in Treatment of High-Risk Ovarian Cancer—A Cost-Effectiveness Analysis
Chan, J. K., Herzog, T. J., Hu, L., Monk, B. J., Kiet, T. K., Blansit, K., Kapp, D. S., & Yu, X. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0322 · Cited by 38
Profile of farletuzumab and its potential in the treatment of solid tumors
Sato, S., & Itamochi, H. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s98242 · Cited by 37
Specific Immunotherapy in Ovarian Cancer: A Systematic Review
Aalipour, S., Zoghi, S., Khalili, N., Hirbod‐Mobarakeh, A., Emens, L. A., & Rezaei, N. (2016) · Immunotherapy · doi:10.2217/imt-2016-0034 · Cited by 31
Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options
Elit, L. M., & Hirte, H. W. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s30238 · Cited by 30
Fossati, M., Buzzonetti, A., Monego, G., Catzola, V., Scambia, G., Fattorossi, A., & Battaglia, A. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.06.003 · Cited by 28
Seeber, A., Braicu, E. I., Untergasser, G., Nassir, M., Fong, D., Botta, L., Gastl, G. A., Fiegl, H., Zeimet, A. G., Sehouli, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4496 · Cited by 28
Ovarian Cancer: Opportunity for Targeted Therapy
Tagawa, T., Morgan, R. J., Yen, Y., & Mortimer, J. E. (2011) · Journal of Oncology · doi:10.1155/2012/682480 · Cited by 28
The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial
Hinde, S., Epstein, D. M., Cook, A. D., Embleton-Thirsk, A., Perren, T. J., & Sculpher, M. J. (2016) · Value in Health · doi:10.1016/j.jval.2016.01.013 · Cited by 28
The Current Status of PARP Inhibitors in Ovarian Cancer
McLachlan, J., George, A. J., & Banerjee, S. N. (2016) · Tumori Journal · doi:10.5301/tj.5000558 · Cited by 28
Grigoryan, E. N., & Markitantova, Y. V. (2016) · Biomedicines · doi:10.3390/biomedicines4040028 · Cited by 28
Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cance
López‐Guerrero, J. A., Romero, I., & Poveda, A. M. (2015) · 癌症:英文版 · doi:10.5732/cjc.014.10278 · Cited by 27
Matulonis, U. A., Wulf, G. M., Barry, W. T., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-ct324 · Cited by 21
Development of the short version of the Gynecologic Cancer Lymphedema Questionnaire: GCLQ-7
김세익 (2017) · Journal of Gynecologic Oncology · Cited by 21
Michalarea, V., Lorente, D., Lopez, J., Carreira, S., Hassam, H., Parmar, M., Sathiyayogan, N., Turner, A., Hall, E., Fandos, S. S., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-ct323 · Cited by 16
Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy
Kluzek, K., Białkowska, A., Koczorowska, A. M., & Zdzienicka, M. Z. (2012) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/17322693.1000548 · Cited by 10
Cited by
Ovarian cancer: Current status and strategies for improving therapeutic outcomes
Chandra, A., Pius, C., Nabeel, M., Nair, M., Vishwanatha, J. K., Ahmad, S., & Basha, R. (2019) · Cancer Medicine · doi:10.1002/cam4.2560 · Cited by 449
Ovarian Cancer Immunotherapy and Personalized Medicine
Morand, S., Devanaboyina, M., Staats, H., Stanbery, L., & Nemunaitis, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126532 · Cited by 372
The Influence of Cell Cycle Regulation on Chemotherapy
Sun, Y., Liu, Y., Ma, X., & Hu, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136923 · Cited by 290
Drug resistance in ovarian cancer: from mechanism to clinical trial
Wang, L., Wang, X., Zhu, X., Zhong, L., Jiang, Q., Wang, Y., Tang, Q., Li, Q., Zhang, C., Wang, H., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01967-3 · Cited by 255
Tumor microenvironment in ovarian cancer: function and therapeutic strategy
Yang, Y., Yang, Y., Yang, J., Zhao, X., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00758 · Cited by 218
Metadata
- Authors
- Cortez, A. J., Tudrej, P., Kujawa, K. A., & Lisowska, K. M.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2017-12-16
- Volume
- 81
- Issue
- 1
- Pages
- 17-38
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2771491442
- Cited by
- 624
- References
- 102
- FWCI
- 47.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.